Abstract Nociceptin/orphanin FQ (N/OFQ), added in vitro to murine spleen cells in the picomolar range, suppressed antibody formation to sheep red blood cells in a primary and a secondary plaque-forming cell assay. The activity of the peptide was maximal at 10 −12 M, with an asymmetric U-shaped dose-response curve that extended activity to 10 −14 M. Suppression was not blocked by pretreatment with naloxone. Specificity of the suppressive response was shown using affinity-purified rabbit antibodies against two N/OFQ peptides and with a pharmacological antagonist. Antisera against both peptides were active, in a dose-related manner, in neutralizing N/OFQ-mediated immunosuppression, when the peptide was used at concentrations from 10 −12.3 to 10 −11.6 M. In addition, nociceptin given in vivo by osmotic pump for 48 h suppressed the capacity of spleen cells placed ex vivo to make an anti-sheep red blood cell response. These studies show that nociceptin directly inhibits an adaptive immune response, i.e., antibody formation, both in vitro and in vivo.
Introduction
Nociceptin/orphanin FQ (N/OFQ) is a heptadecapeptide encoded by a full-length cDNA, which was first identified in mammalian brain tissues (Meunier et al. 1995; Reinscheid et al. 1995) . N/OFQ is processed from a polypeptide precursor (PPNOC) and shares a high structural homology with the opioid peptide, dynorphin A (Meunier et al. 1995; Reinscheid et al. 1995; Houtani et al. 1996) . However, N/OFQ does not bind to the delta opioid receptor or to either of the two other opioid receptors, mu and kappa (Mollereau et al. 1994; Pan et al. 1995) . N/OFQ was found to be the natural ligand for the orphan opioid receptor-like 1 (ORL1) receptor which was cloned from the neural tissue of humans (Mollereau et al. 1994) , rats (Bunzow et al. 1994; Chen et al. 1994; Wick et al. 1994; Fukuda et al. 1994) , and mice (Halford et al. 1995) . N/OFQ and ORL-1 were initially linked to the opioid system because of: (1) the 60% homology of N/OFQ to other opioid peptides; (2) the similarity of the precursor proteins in the two systems; and (3) the observations that the ORL-1 receptor, like the opioid receptors, was a G-protein coupled, seven transmembrane protein, which when bound to N/OFQ resulted in inhibition of forskolin-induced cAMP accumulation via a pertussis toxin-sensitive Gi protein (Chen et al. 1994; Reinscheid et al. 1995; Civelli 2008) . However, ligands for opioid receptors were not active at ORL-1 (Bunzow et al. 1994; Mollereau et al. 1994; Wang et al. 1994; Reinscheid et al. 1998; Meng et al. 1996) , and the activity of ORL-1 in neuronal tissue was found to be naloxone insensitive in vitro (Knoflach et al. 1996; Reinscheid et al. 1995) and in vivo (Chen et al. 2001 ). These latter findings indicated that ORL-1 is not a classical opioid receptor. Using in situ hybridization and immunohistochemistry, studies showed that N/OFQ and ORL-1 are widely expressed in the brain and peripheral nervous system of mammals (Neal et al. 1999b; Peluso et al. 1998; Bunzow et al. 1994; Mollereau et al. 1994; Fukuda et al. 1994; Neal et al. 1999a; Houtani et al. 1996; Anton et al. 1996; Reinscheid and Civelli 2002) , as well as in peripheral tissues, such as the intestines, skeletal muscle, vas deferens, and the spleen (Wang et al. 1994) . Studies on the function of N/OFQ discovered a broad spectrum of bioactivities in a variety of complex neural functions, such as nociception (Mogil and Pasternak 2001) , neuroendocrine control (Bryant et al. 1998) , water-electrolyte balance (Kapusta et al. 1997) , sexual behavior (Sinchak et al. 2007 ), alimentary responses (Olszewski and Levine 2004; Polidori et al. 2000) , learning and memory (Mogil and Pasternak 2001) , kindling and epilepsy (Gutiérrez et al. 2001 ), stress and anxiogenic activity (Green et al. 2007) , locomotor activity and reward (Mogil and Pasternak 2001) , and drinking behavior (Ciccocioppo et al. 2002) .
An interesting observation is that the N/ORL-1 message is highly expressed in cells of the immune system, and in several cases these cells have been found to produce N/ORL-1 peptide. Human peripheral blood leukocytes and spleen cells, as well as mouse splenocytes, have been shown to express message for N/ORL (Halford et al. 1995; Wick et al. 1995; Hazum et al. 1979; Peluso et al. 1998) . Initially, T cells were identified as positive for message, which was shown to be significantly upregulated after treatment with mitogens (Wick et al. 1995; Arjomand et al. 2002) . Subsequently, message was also demonstrated in human monocytes (Serhan et al. 2001) , in monocytic cell lines (THP and U937; Peluso et al. 1998 Peluso et al. , 2001 ) and human peripheral blood polymorphonuclear (PMN) leukocytes (Peluso et al. 1998; Serhan et al. 2001; Fiset et al. 2003) . In addition, human B cell (Hom et al. 1999 ) and T cell lines were shown to express N/ORL message constitutively (Wick et al. 1995; Peluso et al. 1998) . A functional role for the receptors is implied by the observation that monocytic, T cell, and B cell lines, as well as primary human PMNs, bind N/OFQ at levels comparable to those exhibited by human SH-SY5Y neuroblastoma cells (Peluso et al. 2001; Hom et al. 1999; Serhan et al. 2001; Krüger et al. 2006) . Nociceptin is present in human neutrophil granules (PMNs) and excreted upon PMN degranulation (Fiset et al. 2003) . Rat splenocytes have also been shown to excrete N/OFQ when stimulated with mitogens, proinflammatory cytokines, and other classes of compounds, indicating that leukocytes can be a source of this neuropeptide (Miller and Fulford 2007) . However, a clear role for N/OFQ in the immune system is still to be determined. Exogenous N/OFQ has been shown to be both proinflammatory and anti-inflammatory, immunoenhancing, and immunosuppressive. Evidence suggesting a proinflammatory role includes the following. Mice lacking the gene for the precursor for N/OFQ have decreased proinflammatory cytokine responses to staphylococcal enterotoxin A (SEA; Goldfarb et al. 2006) , and its absence decreases murine experimental colitis Szalay et al. 2004; Kato et al. 2005 ). Mice injected with N/OFQ have increased levels of mRNA for tumor necrosis factor (TNF)-α and IFN-γ in their spleens when subsequently injected with SEA (Goldfarb et al. 2006) . N/OFQ is chemotactic for PMNs and human monocytes in vitro and in vivo (Serhan et al. 2001; Fiset et al. 2003; Trombella et al. 2005) . Human T cells activated with staphylococcal enterotoxin B (SEB) show increased proliferation in response to nociceptin and upregulated expression of the costimulatory molecule CD28 (Waits et al. 2004) . Further, antisense to ORL-1 was shown to suppress the polyclonal IgM and IgG responses of mouse spleen cells stimulated with lipopolysaccharide by 50%, suggesting that the peptide exerts a functional role in immunocompetence (Halford et al. 1995) . In contrast to the proinflammatory role suggested by these observations, N/ORL has also been reported to suppress the production of chemokine proteins (i.e., CCL2/MCP-1 and CCL5/RANTES) in human monocytes and monocyte-like cell lines (Kaminsky and Rogers 2008) and to inhibit the proliferation of Con-A-activated rat splenocytes, as well as the production of interleukin (IL)-2 in vitro (Miller and Fulford 2007) . The peptide has been reported to decrease expression of mRNA for TNF-α, IL-1β, and IL-6 in astrocytes activated in vivo by peripheral administration of an inflammatory stimulus and also by astrocyte cultures stimulated in vitro with lipopolysaccharide (Fu et al. 2007 ).
Most of the above studies on the effect of N/ORL on immune responses measured parameters of innate immune responses or of nonspecific immune responses, for example responses to mitogens, cytokine levels, or polyclonal immu-noglobulin responses. The present studies were undertaken to examine the effect of nociceptin on an adaptive immune parameter, namely the capacity of mouse spleen cells to mount an in vitro or ex vivo antibody response to sheep red blood cells (SRBCs). Previous studies from our laboratory have shown that mu, kappa, and delta opioid agonists are suppressive in these assays (Bussiere et al. 1993; Eisenstein et al. 1995; unpublished observation) . N/ORL was tested by application directly to spleen cells in vitro and also by in vivo infusion using Alzet® pumps and testing of spleen cells from treated mice ex vivo. In both paradigms, suppression of antibody responses by N/ORL was observed.
Materials and methods
Animals Six-week-old specific pathogen-free C3HeB/FeJ female mice were purchased from Jackson Laboratories (Bar Harbor, ME, USA). New Zealand White male rabbits (2.5 kg) were purchased from Harlan S.A., Mexico.
Primary and secondary in vitro plaque-forming cell antibody responses Immune function was assessed using in vitro plaque-forming cell (PFC) assays that measure the capacity of spleen cells to mount an antibody response to SRBCs, according to the method of Mishell and Dutton (1967) . For the primary PFC assay, mice were sacrificed and their spleens aseptically removed. A single-cell suspension of spleen cells was obtained by pushing the spleen through nylon mesh bags in HEPES-buffered Roswell Park Memorial Institute (RPMI)-1640 (InVitrogen GIBCO, Grand Island, NY, USA) supplemented with 5% fetal bovine serum (FBS). Red blood cells were lysed by hypotonic shock with sterile water. Cells were washed twice and resuspended in tissue culture medium consisting of RPMI-1640 supplemented with 10% FBS, 2 mM Lglutamine, 50 μg/ml gentamicin, 1 mM nonessential amino acids, 1 mM sodium pyruvate, 10 μg/ml of adenosine, uridine, cytosine, and guanosine, and 0. For the secondary PFC assay, mice were immunized in vivo 14 days before spleen harvest with a 10% suspension of SRBC given i.p. in 0.2 ml of phosphate-buffered saline (Eisenstein et al. 1995) . The spleens of the SRBC-primed mice were removed and processed in the same manner as for the primary PFC assay described above. Unfacilitated plaques were counted, which represents cells producing IgM antibodies to SRBC. The number of plaques in spleen cell cultures which did not receive treatment with N/OFQ was in the range of 1,000 to 2,500 for the primary PFC assay and 3,000 to 5,000 for the secondary PFC assay. If less than 500 plaques were detected in control wells, the experiment was discarded.
Viability of cultures was assessed by Trypan blue exclusion at the time of cell harvest on day 5 after culture.
In vivo treatment with N/OFQ Alzet® osmotic minipumps, Model 1003D (DURECT Corp., Cuppertino, CA, USA), were used to administer agonists in vivo. The pumps used deliver 1 μl/h; therefore, the dose in milligram per kilogram per day had to be calculated on the basis of milligram per kilogram per 24 μl. The doses of N/OFQ or morphine were calculated by weighing the mice to obtain a mean weight in kilograms, then making solution strengths such that the desired dose per kilogram per day was contained in 24 μl, which was given over the course of 1 day. Mice were anesthetized with methoxyflurane, and an area of the back was shaved. A 1-cm incision was made in the skin, and a pump filled with either saline, N/OFQ in saline, or morphine sulfate in saline was implanted subcutaneously. The incision was closed with Auto-Clip® wound clips (Becton Dickenson, Sparks, MD, USA). After 48 h, mice were sacrificed and spleens removed and placed in vitro in single-cell suspension to assess immune function by the Mishell-Dutton plaque-forming cell assay described above.
Synthesis of peptides for antibody production Peptide antigens used for immunization and assays consisted of the C-termini truncated N/OFQ 1-13 (F-11-K) and the N/OFQ 1-15 [F-13-A] peptide fragments in addition to the full-length N/OFQ1-17 [F-15-Q] nociceptin sequence. Peptides were synthesized on 2-chlorotrityl resin (Anaspec Inc.) using standard Fmoc solid-phase procedures (Hockfield et al. 1993) . Purity was achieved with RP-HPLC and structural integrity verified by LC-MS-MS. The N/OFQ peptide analog Y-15-Q was used as the 125 I-labeled tracer in radioimmunoassays (RIAs) for N/OFQ 1-17. The synthetic dynorphin A 1-17 (Dyn A 1-17 ), Met-Enkephalin (ME), Leu-Enkephalin (LE), and BAM-18 were used as competitive peptide antigens in the assays.
Production of polyclonal antibodies to N/OFQ Adult (2 kg) New Zealand white male rabbits were used to generate specific antisera against N/OFQ 1-13 (F-11-K), N/OFQ1-15 [F-13-A] , and N/OFQ 1-17 [F-15-Q] peptides as haptenized antigens. Synthetic peptides were covalently conjugated to KLH (Sigma-Aldrich) as the protein carrier using standard aldehyde cross-linking procedures (Harlow et al. 1988) . Antisera generated against each peptide fragment were raised according to standard immunization protocols (Harlow et al. 1988) , and standard solid-phase antibody capture enzyme-linked immunosorbent assays (ELISAs; Harlow et al. 1988) were used for identification and titering of productive sera. High titers (>1:100,000) of reactive sera were detected from rabbits C-1 and C-4, the C-1 rabbit being immunized with a conjugate mixture of N/OFQ 1-13 [F-11-K] plus N/OFQ 1-17 (F-15-Q) and the C-4 rabbit with N/OFQ 1-15 [F-13-A] plus N/OFQ 1-17 (F-15-Q). Whole reactive antisera were antigen-affinity-purified through standard affinity chromatography procedures (Harlow et al. 1988 ) using N/OFQ peptide antigens coupled to epoxyactivated Sepharose 6B resin columns (Amersham Pharmacia Biotec, NJ, USA). The recovery of specific C-1 and C-4 antigen-affinity-purified antisera (A-APA) verified by the standard antibody capture ELISA assay (data not shown).
Characterization of cross-reactivity of both C-1 and C-4 A-APA for structurally related peptides to N/OFQ A standard dot blot assay (Gutiérrez et al. 2001 ) was used to screen the specificities of both C-1 and C-4 A-APA against membrane-spotted N/OFQ synthetic peptide antigens and structurally related neuropeptides, such as dynorphin A 1-17 , Met-Enkephalin, Leu-Enkephalin, and BAM-18, tested as potential cross-reactive antigens. Complementary testing for A-APA specificities was carried out using a solid-phase RIA for N/OFQ 1-17 peptide adapted from Hockfield (1993) . The N/OFQ 1-17 peptide analog, Y-15-Q, was radioiodinated using the chloramine-T method. The solid phase of the assay was prepared by adding sequentially Protein-A and C-1 or C-4 A-APA to Immulon II removable wells at dilutions previously determined to provide approximately 20-30% of the peptide tracer binding. Competitive peptides (1×10 −6 -1.5×10 −17 M in quadruplicate) plus 125 I-G-15-Q peptide tracer (5,000 c.p.m.) were incubated for generation of typical standard displacement curves. Treated wells were washed out and counted for 4 min in a ten-channel gamma counter (ISO 199 DATA 500, Hewlett-Packard).
Data analysis Suppression index data were analyzed using analysis of variance for fixed effects (between groups and doses). Data from multiple replications and multiple wells were pooled after testing for differences. The suppression index data were transformed to normalized ranks prior to analysis due to failing the Wilk-Shapiro test of normality. Because of the exploratory nature of the experiments, no adjustments were made for multiple comparisons. Comparisons made to the unitary suppression index were based on 95% confidence intervals of the observed means. Data were analyzed using SAS V9.1 (Cary, NC, USA).
Results
Effect of N/OFQ on in vitro spleen cell primary and secondary plaque-forming cell responses Figure 1a shows a titration of N/OFQ to determine its immunosuppressive capacity on mouse spleen cells placed in vitro in a secondary PFC assay. In this paradigm, mice are immunized 14 days before spleen cell harvest with sheep red blood cells. N/OFQ was added to these spleen cells in culture over a wide range of doses from 10 −7 to 10 −16 M.
Immunosuppression was observed at doses between 10
and 10 −14 M, with maximal activity at 10 −13 M. Similar experiments were carried out using a primary PFC assay, where spleen cells were harvested without prior in vivo priming of mice with sheep red blood cells. The results presented in Fig. 1b show that, in the primary PFC assay, N/OFQ exhibited an asymmetric, U-shaped dose-response curve, with immunosuppression in the range of 10 −12 to 10 −14 M, which was maximal at 10 −12 M. No immunosuppression was observed at 10 −11 M. Note that the graph represents a pool of six individual experiments. To assess the receptor specificity of ORL-1 on spleen cells, studies were continued using the primary PFC assay. Previous studies in our laboratory had shown that morphine is suppressive only in the secondary PFC assay (Bussiere et al. 1993; Eisenstein et al. 1995) . Spleen cells were pretreated with naloxone, a nonspecific opioid receptor antagonist, and as shown in Fig. 2 , it did not block the in vitro immunosuppressive effect of N/OFQ in the primary PFC assay. In contrast, preincubation of the cells with 10 −8 M PG-nociceptin, an antagonist specific to the ORL receptor, completely abrogated the immunosuppressive effect produced by N/OFQ (Fig. 3a) . As immune cells are reported to produce N/OFQ, the effect of PG-nociceptin alone on the PFC response was assessed (Fig. 3b ) and found to have no effect. Neither nociceptin nor PGnociceptin was toxic alone or in combination at the highest concentrations of each that were used (data not shown).
Characterization of affinity-purified antisera to N/OFQ To further show that the immunosuppression induced by the peptide was specific, two antigen-affinity-purified rabbit IgG antibodies were generated, and their specificity was tested by two complementary immunological assays for synthetic N/OFQ 1-17 , in order to assess their use in pharmacological assays for neutralizing the suppressive effect of this peptide. Insets in Fig. 4 show representative dot blots of both C-1 (a) and C4 (b) antisera targeted to the C terminus of N/OFQ which were tested for reactivity to the full-length N/OFQ (lane labeled F-15-Q) and both N/OFQ peptide fragments truncated by either four or two amino acids at the C-terminal end of the N/OFQ 1-17 (lanes labeled F-11-K or F-13-A, respectively), as well as to classical opioid peptides, such as dynorphin 1-17 (Dyn-A), BAM-18 (an adrenal medulla peptide), LE, or ME. As described previously in "Materials and methods," both antisera were raised against a mixture of N/OFQ 1-17 and its truncated peptide analogs F-11-K and F-15-Q and showed reactivity to the three nociceptin peptides which share common structural homology at both core and C-terminal domains, but not to classical opioid encoding structurally related N-terminal opioid peptide motifs with N/OFQ 1-17 (i.e., N/OFQ 1-17 = Phe-Gly-Gly-Phe-Thr; Dyn-A and Leu-enk = Tyr-Gly-Gly-Phe-Leu and Met-enk = Tyr-GlyGly-Gly-Met). These data support the specificity of both C-1 and C-4 A-APA reacting against the C terminus domain of the N/OFQ 1-17 peptide as epitope. To further verify and assess the specificity of both C-1 and C-4 A-APA antisera, a sensitive and specific solid-phase RIA to N/OFQ 1-17 peptide was developed using as labeled tracer the N/OFQ 1-17 peptide analog, ( 125 I)-Y-15-Q. Representative RIAs showing typical displacement standard curves by synthetic N/OFQ 1-17 peptide using the C-1 A-APA is shown in Fig. 4a . This antigen-affinity-purified N/OFQ 1-17 antiserum was capable of detecting synthetic N/OFQ 1-17 peptide at approximately 4.5×10
−10 M at the IC 50 reference value.
Moreover, the smallest measurable displacement detected of synthetic N/OFQ 1-17 at the IC 20 was as low as 2.3×10 −10 M in the same assay and 2.9×10 −9 M at the IC 80 . Reactivities of C-1 A-APA antisera for both C-terminal N/OFQ truncated antigen peptides were 3.4×10 −8 and 6.1×10 −9 M for N/OFQ-F-11-K and N/OFQ-F-13-A at the IC 50 reference value, respectively. In addition, no significant cross-reactivity against dynorphin A, BAM-18, and Leu-enkephalin was observed using 1×10 and 9.3×10 −10 M for N/OFQ-F-11-K and N/OFQ-F-13-A at the IC 50 reference value, respectively. Similar to C-1 A-APA, this antiserum did not show significant cross-reactivity against dynorphin A, BAM-18, or Leu-enkephalin using 1×10 −6 to 1.5×10 −12 M of competitive peptides.
Neutralization of immunosuppression by N/OFQ-specific affinity-purified antisera Both antisera were tested for capacity to neutralize N/OFQ (10 −12 M), in the PFC assay.
As shown in Fig. 5a , both antibodies significantly neutralized N/OFQ in a concentration-related fashion. Neither antiserum alone (at concentrations from 10 μg to 0.16 μg/ml) nor normal rabbit serum had any effect on the PFC response.
(Data for 10 μg/ml are shown in Fig 5a. ) A further experiment was carried out to assess the efficacy of the two antibodies using three different concentrations of N/OFQ, bracketing the 10 −12 -M concentration. As shown in Fig. 5b , both antibodies neutralized the immunosuppressive effect of N/OFQ at all three concentrations of the peptide.
Effect of in vivo administration of N/OFQ on primary PFC responses The immunomodulatory capacity of N/OFQ when given in vivo by an Alzet® pump was assessed. Doses ranging from 0.02 to 2 mg/kg per day were tested. After 48 h of infusion of the peptide, animals were sacrificed and spleens removed and placed ex vivo to examine their capacity to mount a primary PFC response. The results show (Fig. 6 ) that immunosuppression was observed over a wide range of doses, with a maximal effect at 0.05 mg/kg per day. Morphine, at 0.5 mg/kg per day, was included in these experiments as a positive control, as this dose had been shown previously by our laboratories to produce maximal immunosuppression (Rahim et al. 2001) .
Discussion
Cells of the immune system have been shown to produce and have receptors for a variety of neuropeptides including β-endorphin, enkephalins, substance P, and vasoactive intestinal peptide (Smith et al. 1986; Rosen et al. 1989; Lai et al. 1998; Delgado et al. 2004; Mousa et al. 2004) . As documented in the "Introduction," leukocytes have been shown to express message for the ORL-1 receptor, to bind N/OFQ, and even to produce N/OFQ.
The current studies add to the activities of nociceptin in the immune system, demonstrating that the peptide suppresses the capacity of mouse spleen cells to make an antibody plaque-forming response to sheep red blood cells. The current results are novel because they are the first to show that nociceptin modulates an adaptive immune response, antibody production, using a classic assay to assess this parameter. Previous studies have examined the role of nociceptin in inflammation, in innate immune responses, and in nonspecific immune responses, such as responses to mitogens or the capacity to make a polyclonal Serhan et al. (2001) found that the K d for human neutrophils was significantly higher, 1.5 nM. However, the biologic activity of N/OFQ in activating chemotaxis of human neutrophils was maximal at 100 pM. Other neuropeptides, including endomorphins 1 and 2, have also been reported to act on cells of the immune system at these ultralow concentrations (Anton et al. 2008) . Microglia also respond to dynorphin A and to endomorphin 1 in the femtomolar range Peterson et al. 1999) .
In accord with other reports in the literature, using ORL1 in a variety of nonimmune assays, we found that the immunosuppression induced by ORL1 was not inhibited by naloxone. Only one other study of immune parameters tested the effect of naloxone on a functional measure of ORL1 activity (Trombella et al. 2005) , and these investigators reported that 10 −6 M naloxone did not block human monocyte chemotaxis induced by the peptide. In support of the inefficacy of naloxone at the ORL1 receptor, Hom et al. (1999) reported that naloxone did not inhibit binding of radiolabeled N/OFQ in Raji cells. We have previously shown that pretreatment for 2 h with either naloxone or with other mu or kappa receptor selective antagonists completely blocked the immunosuppressive effect of morphine and of the kappa agonist, U50488, in the same PFC assay (Eisenstein et al. 1995) , indicating that the protocol is effective in ability to demonstrate receptor antagonism. In the present studies, in contrast to the inactivity of naloxone, the same incubation protocol using PG-nociceptin was effective in inhibiting the immunosuppressive activity of N/OFQ. To further confirm the specificity of the immunosuppression, two different rabbit antigen-affinity-purified antisera generated in the current study (namely C-1 and C-4 A-APA), each with demonstrated specificity for the C terminus domain of the N/OFQ 1-17 peptide by both immune dot blot and solidphase RIA, both of which inhibited the activity of nociception. It is interesting to note that this study used a vaccination strategy that involved mixing of immunogens containing haptenized both full-length N/OFQ 1-17 and Cterminal truncated N/OFQ peptides (F-11-K and F-13-K) in order to enhance the targeting of the N/OFQ C terminus as the dominant epitope for antibody recognition. Although a detailed N/OFQ1-17 epitope mapping characterization for either C-1 or C-4 A-APA reactive antisera was not approached in the current study, the aforementioned vaccination strategy was successful as confirmed by the dot blot and RIA assays, since no cross-reactivity of either C-1 or C-4 was observed against classical opioid peptides (Mogil and Pasternak 2001) encoding structurally related N-terminal opioid peptide motifs also present in N/OFQ 1-17 (i.e., N/OFQ 1-17 = Phe-Gly-Gly-Phe-Thr; Dyn-A and Leuenk = Tyr-Gly-Gly-Phe-Leu and Met-enk = Tyr-Gly-GlyGly-Met). The fact that the data demonstrate that the antibodies predominantly recognize C-terminal domains of the N/OFQ 1-17 peptide fits with the report of Rossi et al. who showed a critical functional role for the last four Cterminal amino acids encoded into the N/OFQ 1-17 peptide, a structural domain targeted by our C-1 and C-4 A-APA reactive antisera (Rossi et al. 1997) . The data are consistent with an antibody-dependent neutralization of immunosuppression by the N/OFQ 1-17 peptide mediated through the C terminus of the molecule which induces steric-hindrance effects capable of altering peptide binding to ORL-1 receptors expressed on cultured spleen cells. Another issue to be considered is the fact that the dot blot and RIAs assays were designed to determine both sensitivity and specificity of detection of C-1 and C-4 A-APA for the N/OFQ 1-17 peptide. Data presented in Fig. 4 show a very high reactivity capacity in the low picomolar range of C-1 A-APA (4.5×10 −10 M) and C-4 (2.7×10
−10 M) A-APA, respectively, at the IC 50 reference value for the N/OFQ 1-17 synthetic peptide. However, from these data, it is not possible to extrapolate quantitative affinity parameters (i.e., K d s) for the A-APA antisera. Equilibrium dialysis experiments using radiolabeled N/OFQ 1-17 synthetic peptide would be required to determine the K d values. At the present time, we do not have a definitive explanation for why at least two orders of magnitude more antibody (i.e., 6.6×10 −10 -4.6×10 −11 for either C-1 or C-4 A-APA) were required to neutralize the immunosuppressive activity of the N/OFQ 1-17 synthetic peptide in the low to high picomolar range (i.e., 10 −9 to 10 −14 M). One plausible explanation is that our antigen affinity chromatography procedures used for whole reactive C-1 and C-4 sera purification are yielding antigen reactive antibodies contaminated with significant amounts of nonspecific immunoglobulins, which may contribute to UV measurements of apparent specific purified antibodies in chromatographic fractions. Therefore, antisera neutralizing doses in our study could actually be overestimated in the antibody-dependent neutralization assays of immunosuppressive activity of N/OFQ 1-17 . Another possible explanation is that spleen cells produced N/OFQ that bound to the antisera (Miller and Fulford 2007) . The PFC assay used in the present experiments is a measure of antibody formation an adaptive immune response. The assay requires B cells, T cells, and antigen-presenting cells for a functional antibody response. The current experiments do not indicate which cells are the target of ORL1, leading to inhibition of the immune response to sheep red blood cells nor is a mechanism for the inhibition identified. However, it is noteworthy that ORL1 inhibited both the primary and the secondary PFC responses. While a mechanism for the inhibition has not been established in the present studies, Waits et al. found that N/OFQ could upregulate CTLA-4 on T cells restimulated with anti-CD3/CD80 (Waits et al. 2004) . Further, N/OFQ induced PGE 2 in human peripheral T cells stimulated with SEB. Both CTLA-4 and PGE 2 are known to have immunosuppressive properties. In the PFC system, there is a complex interaction between three types of cells, and the mechanism of immunosuppression by N/OFQ has not been investigated.
The significance of finding ORL1 and its receptor in abundance in the immune system is still to be defined. As noted by the literature cited in the "Introduction" and above, the majority of the rather limited number of studies on the effects of this peptide in the immune system indicates that ORL1 is immunopotentiating. However, there are several other reports, including the present one, where it has been found to be immunosuppressive. These seemingly conflicting results may be due to dosage, time of exposure to the neuropeptide (and N/OFQ-induced ORL-1 receptor downregulation), species, or assays. ORL1 may have a different effect on an adaptive immune response than on inflammatory and nonspecific immune responses. It is well documented that opioid peptides are immunosuppressive in some assays of immune function and stimulatory in others (Wybran et al. 1979; Sharp et al. 1985; Johnson et al. 1982) , in contrast to morphine, which has been found by almost all investigators to be immunosuppressive in a variety of assays of immune status (Eisenstein and Hilburger 1998) . The current results add to the body of literature showing that the N/OFQ peptide is immunomodulatory and presents new data which show that it inhibits antibody formation in a naloxone-insensitive manner. These observations extend the evidence of intimate connections between the neural and immune systems. Future studies are needed to examine the mechanisms by which nociceptin is immunosuppressive. Exploration of this type of neuroimmune connection remains a fertile area for future research, with a promise of avenues to develop therapeutics to modulate immune status.
